Entyvio subcutaneous — Cigna
Crohn’s Disease – Initial Therapy
Initial criteria
- Patient meets the standard Inflammatory Conditions – Entyvio Subcutaneous Prior Authorization Policy criteria.
- Patient has tried TWO of an adalimumab product, Omvoh subcutaneous, Skyrizi subcutaneous, Tremfya subcutaneous, an ustekinumab subcutaneous product, Zymfentra, Cimzia, or Rinvoq OR patient has already started or is currently undergoing induction therapy with Entyvio IV.
Approval duration
6 months